Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.

By Manuel G Iregui, Suzanne B. Ward, G. Sherman, Victoria J. Fraser, Marin Kollef. Chest, 2002

976 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Critical Care and Intensive Care Medicine, Epidemiology

View Paper: https://www.semanticscholar.org/paper/d47d8d18b71d9c8576adf4bb0f4e71526092669f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

1. 古谷 良輔
2. 山口 和将
3. P. Nordmann
4. S. Cosgrove

In Critical Care and Intensive Care Medicine

1. Yehuda Carmeli
2. 古谷 良輔
3. 山口 和将
4. Theodore J. Iwashyna

In Epidemiology

1. 古谷 良輔
2. 山口 和将
3. P. Nordmann

Citations in the corpus

• Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* (2006, background): “Several other investigators have shown that delayed antimicrobial therapy is associated with increased mortality in communityacquired pneumonia (7–9, 17), nosocomial pneumonia (11, 12), and bacterial meningitis (10, 13).”
• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. (2008, background): “The driving force behind this strategy is the consistent finding that delay in the initiation of appropriate antibiotic therapy for patients with HAP is associated with increased mortality (37, 112, 204).”
• The Timing of Early Antibiotics and Hospital Mortality in Sepsis (2017, background): “While no one recommends delaying antibiotics for sepsis patients, the existing evidence supporting the mortality benefits of earlier antibiotic administration is mixed.(14-30, 32) In a frequently cited study, Kumar and others retrospectively evaluated 2,154 critically ill patients with septic shock ”
• Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. (2007, background): “Early therapy is associated with better outcome [99].”
• Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. (2007, result): “Delay in appropriate therapy has been demonstrated to be a risk factor for mortality in serious infections.(32,33) Moreover, not all apparently appropriate therapies are equally effective versus ESBL producers, and variability in outcomes has been noted even according to the class of agent used, wit”